Case Studies Overview
Publications
2021
Virologic Failure Among Treatment-Experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) VS 3-Drug (3DR) Regimens
Paul E. Sax, Joseph J. Eron, Janna Radtchenko, Helena Diaz-Cuervo, Mark Moore, Steven Santiago, Moti Ramgopal, Karam Mounzer, and Richard A. Elion
ID Week Virtual; 2021 September 29 - October 3
Oral Presented at: ID Week
Conference dates: September 29, 2021 - October 3, 2021
Multinational Evaluation of Comedication and Drug-drug Interactions in Hepatitis C Patients Treated with Pangenotypic Direct-acting Antivirals
Stefano Fagiouli, Scott Milligan, Juan Turnés, Alessandra Mangia, Andreas Hintz, Nicole Wick, Antoni Sicras, Luca DegliEsposti, Frank Tacke, Ramón Morillo, GemaAlvarez Nieto, GeroNiess, Stacey Scherbakovsky, MarinelaMéndez, Hsin-Jung Lin, Kim Vanstraelen, CandidoHernandez, and Tim Umland
Poster Presented at: Global Hepatitis Summit (GHS)
Conference dates: June 18, 2021 - June 20, 2021
Is the Age of Hepatitis C Patients Influencing Rapid Direct-acting Antivrial Treatment Start? Results from a Large Multinational Real-world Dataset
Juan Turnés, Alessandra Mangia, Mandana Khalili, Scott Milligan, Stefano Fagiuoli, Vito Di Marco, George Papatheodoridis, Stanislas Pol, Silvia Rosati, AlnoorRamji, Elisabetta Teti, Lisa Barrett, Montserrat Garcia-Retortillo, Francisco Pérez Hernández, Alexander Wong, Chris Fraser, Sergio Rodriguez-Tajes, Elena Jiménez Mutilo, Luis Morano, Joss O’Loan, Francesca Campanale, Guilherme Macedo, Michele Milella, Christian Brixko, Maria Buti, Maria Fernanda Guerra Veloz, Roberto Ranieri, Sergio Borgia, Annalisa Bascià, ConradoM Fernandez-Rodriguez, Brian Conway, Victor De Lédinghen, Mary Fenech, Pablo Ryan, Ivana Maida, Alexandra Martins, Ioanna Ntalla, Hsin-Jung Lin, Candido Hernandez, Kim Vanstraelen, Stacey Scherbakovsky, and Stephen D Shafran
Global Hepatitis Summit 2020/2021; 2021 June 18-20
Poster Presented at: Global Hepatitis Summit (GHS)
Conference dates: June 18, 2021 - June 20, 2021
Is the Gender of Hepatitis C Patients Influencing Rapid Direct-acting Antiviral Treatment Start? Results from a Large Multinational Real-world Dataset
Alessandra Mangia, Silvia Rosati, Lisa Barrett, ElisabettaTeti, Montserrat Garcia-Retortillo, Elena Jiménez Mutilo, Francesca Campanale, Maria Buti, Maria Fernanda Guerra Veloz, Annalisa Bascià, Mary Fenech, Ivana Maida, Alexandra Martins, Juan Turnés, Scott Milligan, Stefano Fagiuoli, Vito Di Marco, Stephen D Shafran, George Papatheodoridis, Denis Ouzan, AlnoorRamji, Francisco Pérez Hernández, Alexander Wong, Chris Fraser, Sergio Rodriguez-Tajes, Luis Morano, Joss O’Loan, GuilhermeMacedo, Michele Milella, Christian Brixko, Roberto Ranieri, Sergio Borgia, ConradoM Fernandez-Rodriguez, Brian Conway, Victor De Lédinghen, Pablo Ryan, Stacey Scherbakovsky, Hsin-Jung Lin, Kim Vanstraelen, IoannaNtalla, Candido Hernandez, and Mandana Khalili
Global Hepatitis Summit 2020/2021; 2021 June 18-20
Poster Presented at: Global Hepatitis Summit (GHS)
Conference dates: June 18, 2021 - June 20, 2021
Eficacia de sofosbuvir/velpatasvir (SOF/VEL) en pacientes con infección crónica por VHC y trastornos psiquiátricos: resultados en práctica clínica real en 6 países
García-Retortillo M, Milligan S, Barrett L, Teti E, Wedemeyer H, Fraser C, Morano L, Rodríguez-Tajes S, Acosta-López S, O’Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernández-Rodríguez CM, Martins Figueiredo L, Fenech M, Jiménez Mutiloa E, Macedo G, Maida I, Ryan P, Campanale F, Bascia A, Conway B, Ranieri R, Borgia S, De Lédinghen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernández-López C, and Di Marco V
Gastroenterol Hepatol. 2021; 44 Supl Congr 2: 32-118: Abstract #64
Poster Presented at: Spanish Association for the Study of the Liver (AEEH)
Conference dates: June 14, 2021 - June 16, 2021
Prevalence of Drug-Drug Interactions with Pangenotypic Direct-Acting Antivirals for Hepatitis C and Real-World Care Management in the United States: A Retrospective Observational Study
Michael P Curry, MD, Steven L Flamm, MD, Scott Milligan, PhD, Naoky Tsai, MD, Nicole Wick, AS, Zobair Younossi, MD, and Nezam H Afdhal, MD
Manuscript Published in: Journal of Managed Care + Specialty Pharmacy (JMCP)
Date of Publication: June 1, 2021
Variables Associated with Lack of Suppression on Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH) in the US
Richard A Elion, MD, Joe J Eron, MD, Julie Priest, MSPH, Janna Radtchenko, MBA, Moti Rampogal, MD, Alan Oglesby, MPH, and M Keith Rawlings, MD
Poster Presented at: The American Conference For The Treatment Of HIV (ACTHIV)
Conference dates: May 20, 2021 - May 22, 2021
Understanding Real-World Utilization of Pre-Exposure Prophylaxis (PrEP): Data from Trio Health HIV Research Network
Janna Radtchenko, MBA, and Rick Elion, MD
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Management of Gout after Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman, Mona Amin, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Kelsey Milligan, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman, Mona Amin, Kimmi Cox, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Real-World Utilization of Janus Kinase Inhibitors (JAKs) and Biologics in Patients with Rheumatoid Arthritis (RA)
Jasvinder A. Singh, MD, MPH, Janna Radtchenko, MBA, Nehad Soloman, MD, Kwas Huston, MD, Simon M. Helfgott, MD, and Colin C. Edgerton, MD
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Real-World Clinical Characteristics of 112 Patients with Interstitial Lung Disease (ILD); Update from the Trio Health ILD Registry
Frantz RP, Rane D, Nathan SD, Lancaster L, Frost AE, Chakinala MM, Oudiz RJ, and Farber HW
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Comorbid Burden and Survival Risk Metrics of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the TRIO Health PH Registry
Murali Chakinala, Deepali Rane, Ronald Oudiz, Adaani Frost, Robert Frantz, Steven Nathan, and Harrison Farber
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network (ARN)
Simon Helfgott, Deepali Rane, Kent Kwas Huston, Jeremy Broestl, Jasvinder Singh, Nehad Soloman, and Colin Edgerton
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Outcomes with Infliximab and Its Biosimilars in Patients with Rheumatoid Arthritis (RA): Real-World Experience in the US
Simon Helfgott, MD, Janna Radtchenko, MBA, Nehad Soloman, MD, Kent Kwas Huston, MD, Jasvinder Singh, MD, MPH, and Colin Edgerton, MD
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Disparities in Targeted Immune Modulating (TIM) Treatment for Elderly Compared to Younger Patients with Psoriatic Arthritis (PSA)
Jasvinder Singh, Andrew Frick, Simon Helfgott, Kent Kwas Huston, Nehad Soloman, John Tesser, and Colin Edgerton
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Colin Edgerton, Andrew Frick, Simon Helfgott, Ken Kwas Huston, Jasvinder Singh, and Nehad Soloman
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 17, 2021 - May 20, 2021
Comorbid Burden and Survival Risk Metrics of Pulmonary Hypertension (PH) Patients in US-Clinical Care: Real-World Assessments from the TRIO Health PH Registry
Murali Chakinala, Deepali Rane, Ronald Oudiz, Adaani Frost, Robert Frantz, Steven Nathan, and Harrison Farber
DOI: 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1519
Poster Presented at: American Thoracic Society (ATS)
Conference dates: May 14, 2021 - May 19, 2021
Real-World Utilization of Janus Kinase Inhibitors (JAKs) and Biologics in Patients with Rheumatoid Arthritis (RA)
Janna Radtchenko, Jasvinder A. Singh, MD, MPH, Nehad Soloman, MD, Kwas Huston, MD, Simon M. Helfgott, MD, and Colin C. Edgerton, MD
Poster Presented at: Academy of Managed Care Pharmacy (AMCP)
Conference dates: April 12, 2021 - April 16, 2021
A Retrospective Study of Rurioctocog Alfa Pegol and Emicizumab Wastage, Consumption, and Costs in US Clinical Practice Among Patients with Hemophilia A
Shawn X. Sun, Andrew Frick
Poster Presented at: Academy of Managed Care Pharmacy (AMCP)
Conference dates: April 12, 2021 - April 16, 2021
Weight Gain After Switching Different Integrase Strand Transfer Inhibitors (INSTI)
Grace A. McComsey, MD, Paul E. Sax, Keri N. Althoff, Janna Radtchenko, Helena Diaz-Cuervo, Joshua Gruber, Moti Ramgopal, Steven Santiago, Graeme Moyle, Karam Mounzer, and Richard A. Elion
vCROI 2021 Abstract eBook: Page 190-#503
Oral Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)
Conference dates: March 6, 2021 - March 10, 2021
A Retrospective Study of the Impact of Switching Patients with Haemophilia A to Rurioctocog Alfa Pegol or Emicizumab in US Practice
Shawn X. Sun, Andrew Frick
DOI: 10.1111/hae.14236: ABS039
Poster Presented at: European Association for Haemophilia and Allied Disorders
Conference dates: February 3, 2021 - February 5, 2021
2020
Effectiveness of Sofosbuvir/Velpatasvir (SOF/VEL) in Patients with Chronic HCV Infection and Mental Health Disorders: Real-World Care Management from 8 Countries
Milligan S, Barrett L, Teti E, Garcia-Retortillo M, Wedemeyer H, Fraser C, Morano L, Rodriguez-Tajes S, Acosta-Lopez S, O’Loan J, Milella M, Buti M, Guerra Veloz MF, Ramji A, Fernandez-Rodriguez CM, Martins Figueiredo L, Fenech M, Jimenez Mutiloa E, Macedo G, Maida I, Ryan P, Campanale F, Bascia A, Conway B, Ranieri R, Borgia S, De Ledinghen V, Mangia A, Mertens M, Vanstraelen K, Ntalla I, Hernandez-Lopez C, and Di Marco V
Journal of Hepatology. November 2020; 72 (suppl 1): Abstract #905
Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2020
Conference dates: November 13, 2020 - November 16, 2020
Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
Grace A. McComsey, Paul E. Sax, Keri N. Althoff, Todd T. Brown, Janna Radtchenko, Helena Diaz-Cuervo, Moti Ramgopal, Steven Santiago, Graeme Moyle, Karam Mounzer, and Richard A. Elion
ID Week Virtual; 2020 October 21-25: LB-7
Oral Presented at: ID Week
Conference dates: October 21, 2020 - October 25, 2020
Regional and Racial Disparities in Response to Antiretroviral Therapy (ART) Among People Living with Human Immunodeficiency Virus (PLWH)
M Keith Rawlings, MD Additional Authors: Joe J Eron, MD, Julie Priest, MSPH, Janna Radtchenko, MBA, Joe Mrus, MD, Moti Ramgopal, MD, Alan Oglesby, MPH, Faith Fletcher, PhD, and Richard A Elion, MD
ID Week Virtual; 2020 October 21-25: 1704
Poster Presented at: ID Week
Conference dates: October 21, 2020 - October 25, 2020
Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US
Simon Helfgott, Janna Radtchenko, Nehad Soloman, Kent Kwas Huston, Jasvinder Singh, and Colin Edgerton
Arthritis Rheumatol. 2020; 72 (suppl 10)
Poster Presented at: ACR Convergence 2020
Conference dates: November 5, 2020 - November 9, 2020
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network
Simon Helfgott, Jeremy Broestl, Kent Kwas Huston, Deepali Rane, Jasvinder Singh, Nehad Soloman, and Colin Edgerton
Arthritis Rheumatol. 2020; 72 (suppl 10)
Poster Presented at: ACR Convergence 2020
Conference dates: November 5, 2020 - November 9, 2020
Management of Gout After Pegloticase; Observations of US Clinical Practice from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman, Mona Amin, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Kelsey Milligan, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton
Arthritis Rheumatol. 2020; 72 (suppl 10)
Poster Presented at: ACR Convergence 2020
Conference dates: November 5, 2020 - November 9, 2020
Management of Gout with Pegloticase; Real-World Utilization and Outcomes from Trio Health and the American Rheumatology Network (ARN)
Nehad Soloman, Mona Amin, Kimmi Cox, Simon Helfgott, Alexander Hu, Kent Kwas Huston, Jordan Leonard, Scott Milligan, Jasvinder Singh, John Tesser, and Colin Edgerton
Arthritis Rheumatol. 2020; 72 (suppl 10)
Poster Presented at: ACR Convergence 2020
Conference dates: November 5, 2020 - November 9, 2020
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Colin Edgerton, Andrew Frick, Simon Helfgott, Kent Kwas Huston, Jasvinder Singh, and Nehad Soloman
Arthritis Rheumatol. 2020; 72 (suppl 10)
Poster Presented at: ACR Convergence 2020
Conference dates: November 5, 2020 - November 9, 2020
The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases
Kent Kwas Huston, Simon Helfgott, Scott Milligan, Jasvinder Singh, Nehad Soloman, Brandon Weil, and Colin Edgerton
Arthritis Rheumatol. 2020; 72 (suppl 10)
Poster Presented at: ACR Convergence 2020
Conference dates: November 5, 2020 - November 9, 2020
Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak
Kent Kwas Huston, Nehad Soloman, Janna Radtchenko, Simon Helfgott, Jasvinder Singh, and Colin Edgerton
Arthritis Rheumatol. 2020; 72 (suppl 10)
Poster Presented at: ACR Convergence 2020
Conference dates: November 5, 2020 - November 9, 2020
Impact of Adherence on Viral Suppression with Bictegravir and Dolutegravir (DTG)- Containing Triple Therapy in Clinical Practice
Paul E. Sax, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Helena Diaz-Cuervo, Karam Mounzer, Moti Ramgopal, Steven Santiago, and Richard A. Elion
DOI: 10.1002/jia.2.25616: P029
Poster Presented at: HIV Glasgow
Conference dates: October 5, 2020 - October 8, 2020
Association of FIB-4 Score with Major Cardiovascular Events (MACE) in Real-World Populations Diagnosed with NASH or NAFLD in US Clinical Practice
Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal
Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU037
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: August 27, 2020 - August 29, 2020
Association of FIB4 Score with Disease Progression in Real-World Populations Diagnosed with NAFLD/NASH or at Risk of NASH in US Clinical Practice
Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal
Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU036
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: August 27, 2020 - August 29, 2020
Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice
Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal
Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #FRI107
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: August 27, 2020 - August 29, 2020
Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management
Dr. Michael P Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick, and Nezam H Afdhal
Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #THU435
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: August 27, 2020 - August 29, 2020
Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C
Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, and Nezam H Afdhal
Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT387
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: August 27, 2020 - August 29, 2020
Longer-Term Experience with Tenofovir Alafenamimde (TAF) in HBV-Infected Patients : Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression
K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal
Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT457
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: August 27, 2020 - August 29, 2020
Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice
Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal
Journal of Hepatology. August 2020; 73 (suppl 1): Abstract #SAT448
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: August 27, 2020 - August 29, 2020
Global Real-World Evidence of Sofosbuvir/Velpatasvir as Simple, Effective HCV Treatment: Analysis of 5552 Patients From 12 Cohorts
Alessandra Mangia, Scott Milligan, Mandana Khalili, Stefano Fagiuoli, Stephen D. Shafran, Fabrice Carrat, Denis Ouzan, George Papatheodoridis, Alnoor Ramji, Sergio M. Borgia, Heiner Wedemeyer, Ruggero Losappio, Francisco Perez-Hernandez, Nicole Wick, Robert S. Brown Jr., Pietro Lampertico, Karen Doucette, Ioanna Ntalla, Heribert Ramroth, Michael Mertens, Kim Vanstraelen, and Juan Turnes
Manuscript Published in: Liver International
Date of Publication: May 25, 2020
Evaluation of Liver Outcomes Relative to Use of GLP-1 Receptor Agonists (GLP1A) and/or SGLT-2 Inhibitors (SGLT2I) in Real-World Populations Diagnosed With Type II Diabetes (T2DM) and NASH/NAFLD or At Risk of NASH
Michelle Lai, Jeremy Broestl, Andrew Frick, Kavita Juneja, Scott Milligan, Zobair Younossi, and Nezam Afdhal
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2020 - May 20, 2020
Lean and Obese Patients With Non-Alcoholic Steatohepatitis (NASH) / Non-Alcoholic Fatty Liver Disease (NALFD); Comparisons of Populations and Disease Progression
Michelle Lai, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2020 - May 20, 2020
Hepatitis B Treatment Patterns in US Clinical Care Following TAF Approval
Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Kimmi Cox, and Nezam Afdhal
DOI: 10.1016/j.jval.2020.04.484
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2020 - May 20, 2020
Characteristics of Patients Living with HIV (PLWH) and HIV Treatment Outcomes in Community Practices in Southern vs Non-Southern US Regions
Keith Rawlings, MD, Paul Sax, MD, Julie Priest MSPH, Janna Radtchenko, MBA, Joe Mrus, MD, Joe Eron, MD, Alan Oglesby, MPH, Keri Althoff, PhD, Faith Fletcher, PhD, Moti Ramgopal, MD, Steven Santiago, MD, Richard A Elion, MD
23rd International AIDS Conference Virtual; 2020 July 6-10: PEB0354
Poster Presented at: International AIDS Conference (IAS)
Conference dates: July 6, 2020 - July 10, 2020
Patterns of Adherence in Bictegravir and Dolutegravir-Based Regimens
Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, and Richard A. Elion
DOI: 10.1016/j.jval.2020.04.480
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2020 - May 20, 2020
Patterns of Adherence in Bictegravir and Dolutegravir-Based Regimens
Paul E. Sax, Joseph J. Eron, Andrew Frick, Scott Milligan, Moti Ramgopal, Steven Santiago, and Richard A. Elion
The Conference on Retroviruses and Opportunistic Infections (CROI) Virtual; 2020 Mar 8-11: 495
Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)
Conference dates: March 8, 2020 - March 11, 2020
DO PRESCRIBING DATA REFLECT ACTUAL TREATMENT IN PEOPLE WITH HIV?
Joseph J. Eron, Dushyantha Jayaweera, Gregory D. Huhn, Kelsey Milligan, Scott Milligan, Paul E. Sax, Keith Spitz, and Richard A. Elion
The Conference on Retroviruses and Opportunistic Infections (CROI) Virtual; 2020 Mar 8-11: 499
Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)
Conference dates: March 8, 2020 - March 11, 2020
Understanding Who Does and Does Not Gain Weight with Integrase Inhibitors (INSTI)
Grace A. McComsey, Keri N. Althoff, Todd T. Brown, Joseph J. Eron, Gregory D. Huhn, Anthony Mills, Graeme Moyle, Soodi Navadeh, Janna Radtchenko, Paul E. Sax, and Richard A. Elion
The Conference on Retroviruses and Opportunistic Infections (CROI) Virtual; 2020 Mar 8-11: 676
Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)
Conference dates: March 8, 2020 - March 11, 2020
Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV
Sonia Vibhakar Patel, Dushyantha T. Jayaweera, Keri N. Althoff, Joseph J. Eron, Janna Radtchenko, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax, Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn
DOI: 10.1371/journal.pone.0228847
Manuscript Published in: PLOS ONE
Date of Publication: February 13, 2020
Real-World Outcomes Before and After Switching From Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in The United States
Shawn X. Sun, Scott Milligan
Res Pract Thromb Haemost. 2020; 4 (Suppl 1)
Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)
Conference dates: July 12, 2020 - July 14, 2020
A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States
Louis Aledort, MD; Scott Milligan, PhD; Maureen Watt, MSc; and Jason Booth, MPH
DOI: 10.18553/jmcp.2020.26.4.492
Manuscript Published in: Journal of Managed Care & Specialty Pharmacy
Date of Publication: April 1, 2020
Outpatient Costs in Rheumatoid Arthritis (RA) Patients With VS Without Comorbidities
Colin Edgerton, Janna Radtchenko, and V. Michael Holers
DOI: 10.1016/j.jval.2020.04.691
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2020 - May 22, 2020
Real-World Effectiveness of Hepatitis C Virus (HCV) Treatment With Direct-Acting Antivirals (DAA) In Populations With Fatty Liver/Non-Alcoholic Steatohepatitis (FL/NASH), Decompensated Cirrhosis (DCC), Hepatocellular Carcinoma (HCC), and/or Post Liver Transplant (PTX)
Zobair Younossi, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Naoky Tsai, and Nezam Afdhal
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2020 - May 20, 2020
Real-World Effectiveness Of Direct-Acting Antivirals (DAA) In Young Adult (18-25) and Elderly (80+) Populations With Hepatitis C (HCV)
Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Andrew Frick, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2020 - May 20, 2020
Association of FIB-4 score with Major Cardiovascular Events (MACE) in real-world populations diagnosed with NASH or NAFLD in US Clinical Practice
Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal
Oral Presented at: Digestive Disease Week (DDW)
Conference dates: May 2, 2020 - May 5, 2020
Association of FIB4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US Clinical Practice
Michelle Lai, Jeremy Broestl, Andrew Frick, Richard Haubrich, Bruce Koch, Scott Milligan, Macky Natha, Zobair Younossi, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 2, 2020 - May 5, 2020
Use of GLP-1 Receptor Agonists (GLP1a) and/or SGLT-2 Inhibitors (SGLT2i) in Populations with NASH or at Risk of NASH in US Clinical Practice
Michelle Lai, Jeremy Broestl, Kavita Juneja, Scott Milligan, Janna Radtchenko, Zobair Younossi, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 2, 2020 - May 5, 2020
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naıve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Steven L. Flamm, Jens Kort, Steven E. Marx, John Strezewski, Douglas E. Dylla, Bruce Bacon, Michael P. Curry, Naoky Tsai, and Nicole Wick
Manuscript Published in: Advances in Therapy
Date of Publication: April 11, 2020
Real-World Efficacy of Direct Acting Antiviral Therapies in Patients with HIV/HCV
Sonia Vibhakar Patel, Dushyantha T. Jayaweera, Keri N. Althoff, Joseph J. Eron, Janna RadtchenkoI, Anthony Mills, Graeme Moyle, Steven Santiago, Paul E. Sax Jason Gillman, Karam Mounzer, Richard A. Elion, and Gregory D. Huhn
DOI: 10.1371/journal.pone.0228847
Manuscript Published in: PLOS ONE
Date of Publication: February 13, 2020
Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic HCV Infection: A Meta-Analysis
Pietro Lampertico, Jose A. Carrion, Michael Curry, Juan Turnes, Markus Cornberg, Francesco Negro, Ashley Brown, Marcello Persico, Nicole Wick, Ariel Porcalla, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Hu, and Heiner Wedemeyer
Manuscript Published in: Journal Of Hepatology
Date of Publication: February 12, 2020
2019
Real-world effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment naive, noncirrhotic patients with HCV infection in the TRIO network
Michael P. Curry, Jens Kort, Steve Marx, John Strezewski, Nicole Wick, Steven L. Flamm, Bruce Bacon, and Naoky Tsai
Manuscript Published in: GastroHep Wiley
Date of Publication: November 23, 2019
Drug-Drug Interactions (DDIs) with Pangenotypic Direct-Acting Antivirals (DAAs) in Patients with Hepatitis C: Understanding the Populations at Risk and Real-World Care Management
Dr. Michael P. Curry, Prof. Naoky C Tsai, Dr. Bruce R Bacon, Dr. Steven L Flamm, Prof. Zobair M Younossi, MD, MPH, FAASLD, Dr. Scott Milligan, Mrs. Nicole Wick, and Nezam H Afdhal
Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019
Conference dates: November 8, 2019 - November 12, 2019
Pangenotypic Therapies Glecaprevir-Pibrentasvir (GLE-PIB) and Sofosbuvir-Velpatasvir-Voxilaprevir (SOF-VEL-VOX) After Failure with Interferon (IFN)-Free Direct-Acting Antiviral (DAA) Treatment for Hepatitis C” – Poster of Distinction Award
Steven L Flamm, Naoky C Tsai, Bruce R Bacon, Michael P. Curry, Scott Milligan, Nicole Wick, Zobair M Younossi, and Nezam H Afdhal
Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019
Conference dates: November 8, 2019 - November 12, 2019
Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies
R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera
The 17th European AIDS Clinical Society; 2019 Nov 6-9: PE19
Poster Presented at: European AIDS Clinical Society (EACS)
Conference dates: November 6, 2019 - November 9, 2019
Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis
Markus Cornberg, Francesco Negro, Pietro Lampertico, Juan Turnes, Michael P Curry, Ashley Brown, Heiner Wedemeyer, Jose A. Carrion, Nicole Wick, Andreas Pangerl, Eric Crown, Lois Larsen, Yao Yu, and Marcello Persico
Poster Presented at: American College of Gastroenterology
Conference dates: October 25, 2019 - October 30, 2019
Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017
Naoky Tsai, MD, Bruce Bacon, MD, Michael Curry, MD, Steven L. Flamm, MD, Scott Milligan, PhD, Nicole Wick, AS, Zobair Younossi, MD, and Nexam Afhdal, MD
Manuscript Published in: American Journal of Managed Care (AJMC)
Date of Publication: July 12, 2019
Global Real World Evidence of Sofosbuvir/Velpatasvir as Simple, Effective Regimen for the Treatment of Chronic Hepatitis C: Integrated Analysis of 12 Clinical Practice Cohorts
Dr. Alnoor Ramji, Dr. Alessandra Mangia, Dr. Scott Milligan, Prof. Mandana Khalili, Prof. Stefano Fagiuoli, Dr. Stephen D. Shafran, Prof. Fabrice Carrat, Prof. Denis Ouzan, Prof. George Papatheodoridis, Dr. Sergio M. Borgia, Prof. Heiner Wedemeyer, Valeria Piazzolla, Francisco Perez, Ms. Nicole Wick, Dr. Dawn Fishbein, Prof. Pietro Lampertico, Dr. Karen Doucette, Dr. Michael Mertens, Dr. Kim Vanstraelen, Dr. A. Anna Cumaraswamy, and Dr. Juan Turnes
Oral Presented at: Canadian Liver Meeting
Conference dates: May 24, 2019 - May 26, 2019
Access to HCV Cure Under Medicaid Programs in the United States
Zobair Younossi, Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Janna Radtchenko, Naoky Tsai and Nezam Afdhal
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2019 - May 22, 2019
Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging
Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Oral Presented at: Digestive Disease Week (DDW)
Conference dates: April 10, 2019 - April 14, 2019
Real-World Evaluation of NASH in US Clinical Practice: Underutilization of Liver Biopsy and Liver Imaging
Michelle Lai, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US
Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Clinical Practice Experience with Pangenotypic Therapies Glecaprevir-Pibrentasvir and Sofosbuvir-Velpatasvir; Data from the TRIO Network
Michael Curry, Bruce Bacon, Steven Flamm, Nicole Wick, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice
Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal
Journal of Hepatology. October 2019; 70 (suppl 1): Abstract #486
Poster Presented at: American Association for the Study of Liver Disease (AASLD)
Conference dates: November 8, 2019 - November 12, 2019
Longer-Term Experience with Tenofovir Alafenamide (TAF) in HBV-Infected Patients; Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression
K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, and Nezam Afdhal
Journal of Hepatology. October 2019; 70 (suppl 1): Abstract #487
Poster Presented at: American Association for the Study of Liver Disease (AASLD)
Conference dates: November 8, 2019 - November 12, 2019
Clinical Practice Experience with Tenofovir Alafenamide (TAF) for Treatment of Hepatitis B in the US
Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Janna Radtchenko, and Nezam Afdhal
DOI: 10.1016/j.jval.2019.04.883
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2019 - May 22, 2019
Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice
Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal
DOI: 10.1016/S0618-8278(19)30912-0
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Untreated HCV in HIV/HCV-Coinfected US Population Despite an Abundance of Curative Therapies
R. Elion, K. Althoff, J. Eron, J. Gillman, R. Haubrich, G. Huhn, S. Milligan, A. Mills, K. Mounzer, G. Moyle, J. Radtchenko, S. Santiago, P. Sax, and D. Jayaweera
The 17th European AIDS Clinical Society; 2019 Nov 6-9: PE19
Poster Presented at: European AIDS Clinical Society (EACS)
Conference dates: November 6, 2019 - November 9, 2019
Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US
Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Janna Radtchenko, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Jason Gillman, Karam Mounzer, and Rick Elion
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
Weight Gain During Treatment Among 3,468 Treatment-Experienced Adults with HIV
Grace A McComsey, Joseph J Eron, Steven Santiago, Karam Mounzer, Graeme Moyle, Thanes Vanig, Paul E Sax, Keri N Althoff, Scott Milligan, Richard, Haubrich, and Richard A Elion
The Conference on Retroviruses and Opportunistic Infections (CROI) Virtual; 2019 Mar 4-7: 671
Poster Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)
Conference dates: March 4, 2019 - March 7, 2019
Clinical Practice Utilization and Outcomes with Rasburicase Vs Allopurinol for Patients at High Risk of Tumor Lysis Syndrome
Janna Radtchenko, Daniel Lyons, Yvonne Barnes, Scott Milligan, and Edward Drea
DOI: 10.1182/blood-2019-124319
Abstract Presented at: The American Society of Hematology (ASH)
Conference dates: December 7, 2019 - December 10, 2019
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Colin C. Edgerton, Janna Radtchenko, and V. Michael Holers
Arthritis Rheumatol. 2019; 71 (suppl 10): Abstract #1138
Poster Presented at: 2019 ACR/ARP Annual Meeting
Conference dates: November 8, 2019 - November 13, 2019
Misdiagnosis of Desmoid Tumors; Insight From the Desmoid Tumor Research Foundation (DTRF) Patient Registry
Kelly Mercier, Lynn Hernandez, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, and Kelsey Milligan
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 21, 2019 - October 22, 2019
Quality of Life in Pediatric Patients With SYNGAP1-Related Non-Syndromic Intellectual Disability (NSID); Data From the SYNGAP1 (MRD5) Patient Registry
Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov S, and Milligan K
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 21, 2019 - October 22, 2019
The PKU Patient Registry: Understanding The Natural History of PKU
Olaf Bodamer, Harvey Levy, Eileen Blakely, Christine Brown, Hilary Feldman, Rhonda Connolly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Kelsey Milligan, Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 21, 2019 - October 22, 2019
Quality of Life and Demographics of Patients with Immune Thrombocytopenia (ITP); Data from the Platelet Disorder Support Association (PDSA) Patient Registry
Caroline Kruse, Alexandra Kruse, Nancy Potthast, Vanessa Boulanger, Allison Seebald, Suzanne Rossov and Kelsey Milligan
DOI: 10.1097/01.HS9.0000567492.92876.8b
Poster Presented at: European Hematology Association (EHA)
Conference dates: June 13, 2019 - June 16, 2019
Quality of Life (QOL) and Tumor Location in Patients With Desmoid Tumors; Data From The Desmoid Tumor Research Foundation (DTRF) Natural History Study
Kelly Mercier, Lynne Hernandez, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Kelsey Milligan
DOI: 10.1200/JCO.2019.37.15_suppl.e18291 Journal of Clinical Oncology 37, no. 15_suppl
Poster Presented at: ASCO
Conference dates: May 31, 2019 - June 4, 2019
Understanding Disease and Burden in Syngap1-Related Non-Syndromic Intellectual Disability (NSID) Using a Patient Registry Database
Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J.
DOI: 10.1016/j.jval.2019.04.1689
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2019 - May 22, 2019
Understanding Real-World Treatment Patterns and Quality of Life in Patients with Pemphigus and Pemphigoid Using a Patient Registry Database
Yale ML, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J
DOI: 10.1016/j.jval.2019.04.1697
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2019 - May 22, 2019
The Use of a Patient Registry to Better Inform Healthcare Decision Makers and Improve Clinical Outcomes for Patients with Phenylketonuria (PKU)
Bodamer O, Levy H, Blakely E, Brown C, Feldman H, Connolly R, and Moseley K, Boulanger V, Seebald A, Rossov S, Milligan K, Radtchenko J
DOI: 10.1016/j.jval.2019.04.1701
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2019 - May 22, 2019
The Use of Patient Reported Registry Data to Improve Health Outcomes for Patients with Opsoclonus Myoclonus Syndrome (OMS)
Michaelis M, Khoury-Dennis C, Boulanger V, Seebald A, Rossov S, Milligan K, and Radtchenko J
DOI: 10.1016/j.jval.2019.04.1698
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 18, 2019 - May 22, 2019
Understanding Demographics and Diagnosis in Syngap1-related Non-Syndromic Intellectual Disability (NSID) Patients Using a Patient Registry Database
Weldon M, Holder J, Rumbaugh G, Smith-Hicks C, Boulanger V, Seebald A, Rossov K, and Milligan K
The Power of Patients: Informing Our Understanding of Rare Diseases: Posters and Acknowledgements
Poster Presented at: National Institute of Health (NIH)
Conference dates: February 28, 2019 - February 28, 2019
Effectiveness and Safety with Tenefovir Alafenamide (TAF) for Hepatitis B in Patients of Asian Race in US Clinical Practice
Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz, and Nezam Afdhal
DOI: 10.1007/s12072-019-09936-5: Abstract#627
Oral Presented at: Asian Pacific Association for the Study of the Liver (APASL)
Conference dates: February 20, 2019 - February 24, 2019
Real-world, Age-Stratified FVIII Consumption and Bleed Outcomes Before and After Switching to Rurioctocog Alfa Pegol in a Retrospective, Observational Study Using US Specialty Pharmacy Data
Maureen Watt and Scott Milligan
DOI: 10.1182/blood-2019-124101
Poster Presented at: The American Society of Hematology (ASH)
Conference dates: December 7, 2019 - December 10, 2019
A Retrospective, Observational Study Using Specialty Pharmacy Data of Rurioctocog Alfa Pegol Use in the United States
Maureen Watt and Scott Milligan
Poster Presented at: International Society on Thrombosis and Haemostasis (ISTH)
Conference dates: July 6, 2019 - July 10, 2019
Effectiveness of the Salvage Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Chronic Hepatitis C; Clinical Practice Experience from the Trio Network
Bruce Bacon, Michael Curry, Steven L Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 10, 2019 - April 14, 2019
2018
Change in Demographics of Direct-Acting Antiviral (DAA)-Prescribed HCV Patients from 2013 to 2018: Data from 19,994 Patients in the TRIO Network
Naoky Tsai, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 9, 2018 - November 13, 2018
Effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) for Treatment Naïve, Non-Cirrhotic Patients with HCV Infection in the TRIO Health Network
Steven L. Flamm, Jens Kort, Steve Marx, John Strezewski, Bruce Bacon, Michael P. Curry, Naoky Tsai, Nicole Wick, Zobair Younossi and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 9, 2018 - November 13, 2018
Preferences and Outcomes in Clinical Practice with Glecaprevir/Pibrentasvir (GLE-PIB), Ledipasvir/Sofosbuvir (LDV-SOF), and Sofosbuvir/Velpatasvir (SOF-VEL): Data from the TRIO Network
Michael Curry, Bruce Bacon, Steven L. Flamm, Michael Marks, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 9, 2018 - November 13, 2018
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) in Care of Chronic Hepatitis C Patients: Clinical Practice Experience from the TRIO Network
Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 9, 2018 - November 13, 2018
Disparities in Accessing HCV Care Under Medicaid Programs Across the US: Experience from the TRIO Network
Zobair Younossi, Bruce Bacon, Michael Curry, Steven L. Flamm, Scott Milligan, Nicole Wick, Naoky Tsai, and Nezam Afdhal
Oral Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 9, 2018 - November 13, 2018
The Impact of Individual Patient Data in a Network Meta-Analysis: An Investigation into Parameter Estimation and Model Selection
Joy Leahy, Aisling O'Leary, NEzam Afdhal, Emma Gray, Scott Milligan, Malte H. Wehmeyer, and Cathal Walsh
Manuscript Published in: Research Synthesis Methods
Date of Publication: June 20, 2018
Realized Durations of Direct-Acting Antivirals (DAAs) in Care of HCV in US Clinical Practice: Data from the Trio Network
Michael Curry, Bruce Bacon, Steven Flamm, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: Global Hepatitis Summit (GHS)
Conference dates: June 14, 2018 - June 17, 2018
Effectiveness of 8 vs. 12 Week Ledipasvir/ Sofosbuvir (LDV/SOF) in Black, Treatment Naive Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the Trio Network
Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Access to and Utilization of Sofosbuvir/Velpatasvir/Voxilaprevir in Care of Chronic Hepatitis C Patients: Data from the TRIO Network
Bruce Bacon, Michael Curry, Steven Flamm, John Straub, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network
Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: 10.1016/S0016-5085(18)33931-3
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Impact of HCV Viral Load on Elbasvir/ Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network
Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer
DOI: 10.1016/S0016-5085(18)33670-9
Oral Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Real-World Use of Elbasvir-Grazoprevir in Patients with Chronic Hepatitis C: Retrospective Analyses from the TRIO Network
S.L. Flamm, B. Bacon, M. P. Curry, S. Milligan, C. U. Nwankwo, N. Tsai, Z. Younossi, and N. Afdhal
Manuscript Published in: Alimentary Pharmacology & Therapeutics (AP&T)
Date of Publication: April 17, 2018
Effectiveness of 8 vs. 12 Week Ledipasvir/ Sofosbuvir (LDV/SOF) in Black, Treatment Naive Patients with Non-Cirrhotic, Genotype 1 HCV and Baseline Viral Load: Analyses of Real-World Data from the Trio Network
Michael Curry, Bruce Bacon, Steven Flamm, Angela Landen, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network
Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: 10.1016/S0168-8278(18)30723-2
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network
Dushwantha Jayaweera, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: 10.1016/S0168-8278(18)30735-9
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Utilization and Outcomes of Elbasvir/Grazoprevir in Genotype 1B Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Naoky Tsai, Bruce Bacon, Michael Curry, Steven Flamm, Scott Milligan, Chizoba Nwankwo, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Effectiveness of Elbasvir/Grazoprevir in Patients with Cirrhotic Genotype 1 or 4 Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Michael Curry, Steven Flamm, Bruce Bacon, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Impact of HCV Viral Load on Elbasvir/ Grazoprevir Effectiveness in Chronic Hepatitis C: Updated Retrospective Data Analyses from the TRIO Network
Steven Flamm, Bruce Bacon, Michael Curry, Scott Milligan, Chizoba Nwankwo, Naoky Tsai, Nicole Wick, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Clinical Observations of Antiretroviral (ART) Switching in HIV-Suppresed Patients After Availability of TAF
Richard Elion, Joseph Eron, Steven Santiago, Paul Sax, Moti Ramgopal, Greg Huhn, Scott Milligan, Keri Althoff, and Jonathan Winston
DOI: 10.1002/jia.2.25187: P114
Poster Presented at: HIV Glasgow
Conference dates: October 28, 2018 - October 31, 2018
Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network
Rick Elion, Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, and Karam Mounzer
DOI: 10.1016/S0016-5085(18)33670-9
Oral Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network
Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: 10.1016/S0016-5085(18)33931-3
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
Behavioral and Clinical Factors and Direct Acting Antiviral Effectiveness in HCV/HIV Co-Infection: Clinical Experience from the TRIO Network
Gregory Huhn, Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: 10.1016/S0168-8278(18)30723-2
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 11, 2018 - April 15, 2018
Untreated HCV in HIV/HCV Co-Infection: Data from the TRIO Network
Dushyantha Jayaweera, Keri Althoff, Joseph Eron, Gregory Huhn, Scott Milligan, Anthony Mills, Graeme Moyle, Steven Santiago, Paul Sax, Gene Voskuhl, David Wyles, Karam Mounzer, and Rick Elion
DOI: 10.1016/S0168-8278(18)30735-9
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: June 2, 2018 - June 5, 2018
The Opsoclonus Myoclonus Syndrome (OMS) Registry: A Vehicle to Better Understand the Natural History and Experience of OMS Patients
Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
Symptoms and Diagnosis of Opsoclonus Myoclonus Syndrome (OMS): Early Data from the OMS Registry
Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
Treatment Utilization by Patients with Opsoclonus Myoclonus Syndrome (OMS): Insights from the OMS Registry
Mike Michaelis, Christy Khoury-Dennis, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
NORD RareCare® Assistance Programs: Helping the Rare Disease Community Access Diagnostics and Care
Jill Pollander, Pamela Gavin, and Jeremy Broestl
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
The Pemphigus-Pemphigoid Registry: Real-World Diagnostic and Treatment Patterns
Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
The Pemphigus-Pemphigoid Registry: First Report of Patient Quality of Life Measures
Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
The Pemphigus-Pemphigoid Registry: A Platform to Improve Understanding and Advance Care
Marc L. Yale, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
The PKU Patient Registry: A Step for Better Disease Awareness and Improved Patient Outcomes
Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
The PKU Patient Registry: Understanding Diagnosis and Medical History of Patients with PKU
Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
The PKU Patient Registry: Evaluating Treatment Paradigms of Patients with PKU
Eileen Blakely, Christine Brown, Olaf Bodamer, Harvey Levy, Hilary Feldman, Rhonda Connelly, Kathryn Moseley, Vanessa Boulanger, Allison Seebald, Suzanne Rossov, Scott Milligan, and Janna Radtchenko
Poster Presented at: National Organization for Rare Disorders (NORD)
Conference dates: October 15, 2018 - October 16, 2018
Treatment of Hepatitis B in the US: Real-World Evidence from the TRIO Network
Ho Bae, Michael Curry, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal
Journal of Hepatology. October 2018; 68 (suppl 1): Abstract #445
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 9, 2018 - November 13, 2018
Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice: Real-World Evidence from the TRIO Network
Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, and Nezam Afdhal
Journal of Hepatology. October 2018; 68 (suppl 1): Abstract #423
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 9, 2018 - November 13, 2018
A Retrospective, Observational Study of BAX 855 in Clinical Practice in the United States
J. Booth, M. Watt, S. Milligan, and L. Aledort
DOI: 10.18553/jmcp.2018.24.4-a.s1
Poster Presented at: Academy of Managed Care Pharmacy (AMCP)
Conference dates: April 23, 2018 - April 26, 2018
2017
Real-World Patterns of Therapy Utilization and Outcomes in 8,049 HCV Patients: Data from the TRIO Network
Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Drivers of Therapy Choice in Genotype 1 HCV: Analyses of Real-World Data from the TRIO Network
M. Curry, B. Bacon, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
HCV Treatment Failure in the Era of Direct-Acting Antivirals (DAAs): Analyses of Real-World Data from the TRIO Network
Bruce Bacon, Steven L. Flamm, Michael Curry, Douglas T. Dieterich, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Cure Denied and Cure Delayed in Chronic Hepatitis C; Monitoring Non-Start Rates and Increased Time to Start Using Real-World Data from the TRIO Network
Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Impact of Treatment Duration and Ribavirin (RBV) Addition on Real-World Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Select Patient Subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the TRIO Network
C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR-GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A Resistance-Associated Substitutions (RASs)
C. Nwankwo, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: October 20, 2017 - October 24, 2017
Real-World Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from the TRIO Network
S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 6, 2017 - May 9, 2017
Sofosbuvir/Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV
Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Oral Presented at: Digestive Disease Week (DDW)
Conference dates: May 6, 2017 - May 9, 2017
Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network
N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 6, 2017 - May 9, 2017
Access to HCV Care for 31,154 Patients in the United States: Real-World Experience from the TRIO Network
Zobair Younossi, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 6, 2017 - May 9, 2017
Sofosbuvir/Velpatasvir Compared to Existing Standards of Care in GT2-6 HCV
Michael Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Oral Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
Real-World Treatment Utilization and Results in the Renaissance of HCV Care: Analyses of Treatment for 8,955 Patients from The TRIO Network
S.L. Flamm, B. Bacon, M. Curry, D. Dieterich, K. Kowdley, S. Milligan, N. Tsai, Z. Younossi, and N. Afdhal
Oral Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
Utilization of DAA Therapies Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Patients with Genotype 1 HCV: Real-World Experience from the TRIO Network
N. Tsai, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, Z. Younossi, and N. Afdhal
Oral Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
Elbasvir/Grazoprevir Effectiveness in Patients with Chronic Hepatitis C and Chronic Kidney Disease: Real-World Experience from the TRIO Network
Z. Younossi, B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, N. Tsai, and N. Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
Real-World Use of Elbasvir/Grazoprevir and Outcomes in Patients with Chronic Hepatitis C: Retrospective Data Analyses from the TRIO Network
B. Bacon, M. Curry, D. Dieterich, S.L. Flamm, K. Kowdley, S. Milligan, C. Nwankwo, N. Tsai, Z. Younossi, and N. Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2017 - April 17, 2017
2016
Effect of Ethnicity on HCV Patient Outcomes and Access to Therapy in Era of All DAA Regimens: Real-World Experience from the TRIO Network
Kevin Korenblat, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Kris V. Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 11, 2016 - November 15, 2016
Real-World Effectiveness for 12 Weeks of Ledipasvir-Sofosbuvir for Genotype 1 Hepatitis C: the Trio Health Study
E. B. Tapper, B. R. Bacon, M. P. Curry, D. T. Dieterich, S. L. Flamm, L. E. Guest, K. V. Kowdley, Y. Lee, N. C. Tsai, Z. M. Younossi, and N. H. Afdhal
Manuscript Published in: Journal of Viral Hepatitis
Date of Publication: October 11, 2016
Evaluation of Proton Pump Inhibitor Use on Treatment Outcomes With Ledipasvir and Sofosbuvir in a Real-World Cohort Study
Elliot B. Tapper, Bruce R. Bacon, Michael P. Curry, Douglas T. Dieterich, Steven L. Flamm, Lauren E. Guest, Kris V. Kowdley, Yoori Lee, Naoky C. Tsai, Zobair M. Younossi, and Nezam H. Afdhal
Manuscript Published in: Hepatology
Date of Publication: August 17, 2016
Effectiveness of 8 or 12 week LDV/SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network
Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 21, 2016 - May 25, 2016
Effectiveness of 12 or 24 week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network
Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi
Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Conference dates: May 21, 2016 - May 25, 2016
Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network
Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 24, 2016
Access to Therapy in Era of DAA Regimens: Real-World Experience from the TRIO Network
Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 24, 2016
Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network
Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 21, 2016 - May 24, 2016
Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Post-Transplant Patients: Real-World Heterogeneous Population from the TRIO Network
Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: International Liver Transplantation Society (ILTS)
Conference dates: May 4, 2016 - May 7, 2016
Ledipasvir/Sofosbuvir+/-Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the TRIO Network
Douglas T. Dieterich, Bruce Bacon, Michael Curry, Steven L. Flamm, Lauren Guest, Kris Kowdley, Yoori Lee, Zobair Younossi, Naoky Tsai, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2016 - April 17, 2016
Ledipasvir/Sofosbuvir+/-Ribavirin in HCV Post-Transplant Patients: Real-world Heterogeneous Population from the TRIO Network
Steven L. Flamm, Bruce Bacon, Michael Curry, Douglas T. Dieterich, Lauren Guest, Kris Kowdley, Yoori Lee, Naoky Tsai, Zobair Younossi, and Nezam Afdhal
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2016 - April 17, 2016
No Effect of Proton Pump Inhibitor (PPI) Use on SVR with Ledipasvir/ Sofosbuvir (LDV/SOF): Real-World Data from 2,034 Genotype 1 Patients in the TRIO Network
Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 13, 2016 - April 17, 2016
Evaluation of Efficacy of Ledipasvir/Sofosbuvir for 12 weeks in a Real Life Population of Genotype 1a and 1b HCV Patients: Data from the TRIO Network
Nezam Afdhal, Bruce Bacon, Michael Curry, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi
Poster Presented at: Asian Pacific Association for the Study of the Liver (APASL)
Conference dates: February 20, 2016 - February 24, 2016
Disparate Access to Treatment Regimens in Chronic Hepatitis C Patients: Data from The TRIO Network
Z. M. Younossi, B. R. Bacon, D. T. Dieterich, S. L. Flamm, K. Kowdley, S. Milligan, N. Tsai, and A. Nezam
Manuscript Published in: Journal of Viral Hepatitis
Date of Publication: February 3, 2016
2015
Effectiveness of 8 or 12 week LDV-SOF in Treatment-Naïve Patients with Non-Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network
Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 13, 2015 - November 17, 2015
Effectiveness of 12 or 24 Week LDV-SOF and 12 week LDV-SOF + RBV in Treatment-Experienced Patients with Cirrhotic, Genotype 1 Hepatitis C: Real-World Experience from the TRIO Network
Michael P. Curry, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 13, 2015 - November 17, 2015
Failure with All-Oral DAA Regimens: Academic and Community Treatment of a Real-World Population from the TRIO Network
Nezam Afdhal, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Lauren Guest, Kris V. Kowdley, Yoori Lee, Naoky Tsai, and Zobair Younossi
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 13, 2015 - November 17, 2015
Efficacy Evaluation of 24-week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network
Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 16, 2015 - May 19, 2015
Evaluation of Access to Care in Patients Prescribed Sofosbuvir-Containing Regimens; Data from the TRIO Network
Zobair Younossi, Bruce Bacon, Douglas Dieterich, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, and Naoky Tsai
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 16, 2015 - May 19, 2015
Final Evaluation of HCV Patients Treated with 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population
Douglas Dieterich, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Scott Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 16, 2015 - May 19, 2015
Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients Over 70 Years; Data from the TRIO Network
Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Douglas T. Dieterich
Poster Presented at: Digestive Disease Week (DDW)
Conference dates: May 16, 2015 - May 19, 2015
Final Evaluation of HCV Patients Treated With 12-week Regimens Containing Sofosbuvir +/- Simeprevir in the TRIO Network: Academic and Community Treatment of a Real-World, Heterogeneous Population
Douglas Dieterich, Bruce Bacon, Steven Flamm, Kris Kowdley, Soctt Milligan, Naoky Tsai, Zobair Younossi, and Eric Lawitz
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 22, 2015 - April 26, 2015
Comparison of Sofosbuvir +/- Simeprevir in Heterogeneous, Real-World Populations of HCV Patients over 70 years; Data from the TRIO Network
Naoky Tsai, Bruce Bacon, Steven L. Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Douglas T. Dieterich
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 22, 2015 - April 26, 2015
Efficacy Evaluation of 24-Week SOF + RBV in a Heterogeneous, Real-World Population of Genotype 3 HCV; Data from the TRIO Network
Kris Kowdley, Bruce Bacon, Douglas T. Dieterich, Eric Lawitz, Scott Milligan, Naoky Tsai, Zobair Younossi, and Steven L. Flamm
Poster Presented at: The European Association for the Study of the Liver (EASL)
Conference dates: April 22, 2015 - April 26, 2015
2014
Evaluation of Sofosbuvir and Olysio-Based Regimens in the Trio Network: Academic and Community Treatment of a Real-World, Heterogeneous Population
D Dieterich, B Bacon, S Flamm, K Kowdley, S Milligan, N Tsai, Z Younossi, and E Lawitz
Oral Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 7, 2014 - November 11, 2014
Efficacy of Sofosbuvir and Simeprevir-based Regimens for HCV Treatment-Experienced GT1 Patients in a Real-Life Setting; Data from the TRIO Network
Bruce Bacon, Douglas Dieterich, Steven Flamm, Kris Kowdley, Eric Lawitz, Scott Milligan, Zobair Younossi, and Naoky Tsai
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 7, 2014 - November 11, 2014
Evaluation of Efficacy of Sofosbuvir and Simeprevir-based Regimens in a Real-Life Population of HCV Patients with Cirrhosis; Data from the TRIO Network
Steven Flamm, Bruce Bacon, Douglas Dieterich, Kris Kowdley, Eric Lawitz, Scott Milligan, Naoky Tsai, and Zobair Younossi
Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)
Conference dates: November 7, 2014 - November 11, 2014
